Despite advances in the field of male reproductive health, idiopathic male infertility, in which a man has altered semen characteristics without an identifiable cause and there is no female factor infertility, remains a challenging condition to diagnose and manage. Increasing evidence suggests that oxidative stress (OS) plays an independent role in the etiology of male infertility, with 30% to 80% of infertile men having elevated seminal reactive oxygen species levels. OS can negatively affect fertility via a number of pathways, including interference with capacitation and possible damage to sperm membrane and DNA, which may impair the sperm's potential to fertilize an egg and develop into a healthy embryo. Adequate evaluation of male reproductive potential should therefore include an assessment of sperm OS. We propose the term Male Oxidative Stress Infertility, or MOSI, as a novel descriptor for infertile men with abnormal semen characteristics and OS, including many patients who were previously classified as having idiopathic male infertility. Oxidation-reduction potential (ORP) can be a useful clinical biomarker for the classification of MOSI, as it takes into account the levels of both oxidants and reductants (antioxidants). Current treatment protocols for OS, including the use of antioxidants, are not evidence-based and have the potential for complications and increased healthcare-related expenditures. Utilizing an easy, reproducible, and cost-effective https://doi.org/10. 5534/wjmh.190055 298 www.wjmh.org
INTRODUCTION
Natural conception is a complex process that is achieved in only 76% to 85% of couples within 12 months of regular unprotected intercourse [1] [2] [3] [4] [5] . The International Committee for Monitoring Assisted Reproductive Technologies (ICMART) defines infertility as the inability to conceive after 1 year of regular, unprotected intercourse [6, 7] . The World Health Organization estimates that nearly 190 million people struggle with infertility worldwide and the number of couples seeking medical assistance is steadily rising [8, 9] . Among couples unable to conceive, infertility is partially or wholly attributable to a male factor in approximately 50% of cases ( Fig. 1 ) [10] [11] [12] . A variety of conditions can affect male reproductive potential to different extent and they often coexist (Fig. 2 ) [13] [14] [15] [16] [17] [18] [19] . Paradoxically, on routine assessment, the precise etiology of male factor infertility remains undefined in 30% to 50% of patients, who are subsequently classified as having test to measure ORP may provide a more targeted, reliable approach for administering antioxidant therapy while minimizing the risk of antioxidant overdose. With the increasing awareness and understanding of MOSI as a distinct male infertility diagnosis, future research endeavors can facilitate the development of evidence-based treatments that target its underlying cause.
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THE CONCEPT OF MALE OXIDATIVE STRESS INFERTILITY (MOSI)
There is overwhelming evidence that oxidative stress (OS) plays a significant role in the etiology of male infertility [24] [25] [26] [27] [28] [29] [30] . Seminal reactive oxygen species (ROS) are produced mainly by leukocytes or abnormal and immature spermatozoa, and are a natural byproduct of oxidative metabolic pathways as well as cytosolic and plasma membrane oxidases [31] [32] [33] [34] . ROS are also a natural byproduct of adenosine triphosphate production within sperm cell mitochondria [35] . Small quantities of ROS are required to ensure normal cellular physiological functions, including spermatogenesis and various sperm functions preceding fertilization, such as capacitation and acrosome reaction [32, [36] [37] [38] . When ROS levels increase to a pathological level, the body uses dietary and endogenously produced antioxidants to bring the system back to homeostasis [39] . An imbalance between these two opposing forces, in which ROS outweigh antioxidants, can result in OS, which can negatively affect fertility via a number of pathways. OS interferes with capacitation and may cause sperm membrane and DNA damage, thereby affecting the sperm's potential to fertilize an egg and generate a healthy embryo [32, [40] [41] [42] [43] [44] [45] . Also, OS can trigger formation of genotoxic and mutagenic byproducts in the sperm that may increase the risk of disease in the offspring [46] . Depending on the assay methodology used, recent literature suggests that 30% to 80% of infertile men have elevated seminal ROS levels, a potentially treatable condition [28, 30, 44, [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] . A similarly high incidence of OS was reported in a recent clinical trial, with 83.8% (124 of 148 cases) of idiopathic infertile men having positive seminal oxidation-reduction potential (ORP), a measure of ROS-antioxidant discrepancy [unpublished data].
Male reproductive potential cannot be adequately assessed if seminal OS is overlooked. However, there is currently no consensus concerning either the preferred method to measure OS in the clinical setting nor the diagnostic terminology to define this condition. Therefore, we propose the term Male Oxidative Stress Infertility, or MOSI, as a novel descriptor for infertile men with abnormal semen characteristics and OS, which includes many patients who were previously classified as having idiopathic male infertility (Appendix) [24, 52, [57] [58] [59] . Based on several epidemiologic studies, OS may be present in about 56 million males complaining of infertility, two-thirds of whom are considered to have MOSI (https://www.nichd.nih.gov/health/topics/menshealth/ conditioninfo/infertility) (Fig. 3) [30, [60] [61] [62] [63] . In men with normal semen characteristics who are part of couples experiencing unexplained infertility, the role of OS is not well defined. In our experience, 29 
DIAGNOSIS OF MALE OXIDATIVE STRESS INFERTILITY (MOSI)
Conventional semen analysis was introduced about a century ago and remains the most widely used test for measuring sperm production and quality. In recent years, it has become clear that conventional semen analysis alone is not an adequate surrogate measure of male fecundity [64] , as it is plagued with critical shortcomings such as poor reproducibility, subjectivity, and poor prediction of fertility [65] [66] [67] [68] . Given the limited clinical utility of conventional semen analysis and the pathological consequences and ubiquity of OS among the subfertile male population, we propose the incorporation of ORP as a useful clinical biomarker for MOSI in men with abnormal semen analysis and male infertility [58, [69] [70] [71] [72] . ORP may be used to measure the levels of reductants (antioxidants) and oxidants in a variety of biological fluids [73] and could become an adjunct component of semen analysis due to its robust association with impaired sperm function. A number of assays are available to measure OS including chemiluminescence for ROS, total antioxidant capacity for antioxidants, and the malondialdehyde assay for post-hoc damage from lipid peroxidation [74] [75] [76] . Though useful, these tests are difficult to incorporate into routine use because they are expensive, complex, and time-sensitive, and may also require complex instrumentation, large and neat sample volumes, and extensive technical training (Table 1 ) [76] . Additionally, assay results do not correlate with one another and provide only a single marker of OS-either oxidant levels, antioxidant levels, or post-hoc damage [77] .
To date, measurement of ROS in semen is not often utilized as, depending on the method for ROS assessment, it may be prone to intra-and inter-laboratory variability, high turnaround time and high costs [58, 69, 78] . The advent of new technologies that rapidly detect seminal OS through the assessment of ORP in a reproducible manner using a bench-top analyzer can allow for an accurate and cost-effective diagnosis of MOSI [76, 78, 79] . The Male Infertility Oxidative System (MiOXSYS) is a recently developed assay for the assessment of ORP [69] . The ORP test is novel in the area of infertility and is based on a galvanostatic measure of electrons. MiOXSYS has been developed for easy and quick measurement of ORP in semen [80] . Several negative predictive value [58, 59, 69] (Fig. 4) . Among infertile men, higher ORP levels are observed in cases with abnormal semen parameters versus normal parameters (Fig. 5A , 5B). Analysis of data of 3,966 patients at Hamad Medical Corporation, Doha, Qatar, revealed statistically significant negative correlations between ORP and normal sperm morphology (r=-0.529, p<0.0001), progressive motility (r=-0.463, p<0.0001), and sperm concentration (r=-0.844, p<0.0001). The difference in ORP between normozoospermic (mean: 1.14±0.97 mV/10 6 sperm/mL; median: 0.86 mV/10 6 sperm/mL) and non-normozoospermic (mean: 5.65±11.34 mV/10 6 sperm/ mL; median: 2.04 mV/10 6 sperm/mL) patients was also significant (p<0.0001) (Fig. 5B) . 
MANAGEMENT AND TREATMENT OF MALE OXIDATIVE STRESS INFERTILITY (MOSI)
Despite significant advances in the diagnosis and management of male infertility, there are no evidencebased treatment guidelines available for idiopathic male infertility. Understandably, it is difficult to develop an evidence-based approach for a condition with an unclear etiology. A survey among members of the American Urological Association (AUA) indicated that two-thirds of clinicians use empirical medical therapy (EMT) such as selective estrogen receptor modulators, aromatase inhibitors, and gonadotropins to treat idiopathic male factor infertility [82] . While the role of hormonal therapy in men with an identified abnormality such as hypogonadotropic hypogonadism is well-defined [83] , endocrine imbalance is responsible for approximately 10% of all known causes of infertility [21] . The literature remains inconclusive and controver- OS: oxidative stress.
www.wjmh.org sial regarding off-label EMTs for men with idiopathic infertility [20, 82, [84] [85] [86] [87] , especially in light of their cost and side effects (Table 2) . Although there are several small studies that provide support for pharmacological EMT to treat idiopathic male infertility, there is a lack of robust placebo-controlled trials demonstrating improved live birth outcomes [87] [88] [89] [90] .
For the vast majority of infertile men with no underlying endocrine, bacterial, genetic or anatomical causes of infertility, an alternative approach may be to shift from administering EMTs to identifying potential sources of MOSI and mitigating the sequela. The human body produces endogenous antioxidants in an effort to prevent the damage caused by ROS [91, 92] , but this response is not always adequate, resulting in OS. Several studies have shown that exogenous antioxidants have the capacity to counteract oxidative damage or OS, improving both sperm motility and DNA integrity for infertile men with OS (Table 3) [87] [88] [89] [90] [91] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] . Indeed, many oral formulations of antioxidants are readily available in the market and are commonly used to treat men with infertility. However, there is growing awareness that the indiscriminate use of antioxidants may paradoxically exacerbate sperm cell damage in men without elevated MOSI by inducing a state of reductive stress [52, 112] . In order to prevent Only double blind placebo control studies on idiopathic male infertility patients were included. Except for three studies (94, 96 , and 142), others used a combination of antioxidant supplements for a period of 3 to 6 months.
the inappropriate use of antioxidants, clinical guidelines outlining the effective diagnosis and treatment of MOSI are critical. Several clinical trials and systemic reviews involving the use of various combinations of antioxidants (L-carnitine, selenium, N-acetyl-cysteine, Coenzyme Q10, ubiquinol, vitamin E, vitamin C, and lycopene) in infertile men have reported beneficial effects of antioxidants on sperm concentration, motility, and DNA integrity (Table 4 ) [113] [114] [115] [116] [117] [118] [119] [120] . Preliminary results from a 2018 clinical trial involving 148 idiopathic infertile men indicated that intake of oral antioxidants for a period of three months significantly increased sperm concentration (36%, p<0.0001), progressive motility (100%, p<0.0001), and motility (12%, p=0.0033). Moreover, a significant decrease in ORP (39%, p<0.0001) and SDF (20%, p=0.0002) was observed post-treatment [unpublished data]. These beneficial changes in semen quality have been reported to improve the chance of natural conception in several but not all studies [53, 121] . This benefit could be augmented, and harm prevented, by directing therapy through measuring and monitoring seminal ORP [113] [114] [115] [116] 122, 123] . Identifying and treating MOSI in cases where the use of assisted reproductive technology (ART) is indicated is especially important, as many of the sperm preparation and handling methods used during ART may induce OS, further aggravating the negative impact of MOSI [124, 125] . In couples undergoing ART, diagnosis of MOSI and subsequent antioxidant therapy may improve ART success [122, 126, 127] . Additionally, there is emerging evidence that antioxidant therapy may improve pregnancy outcomes in couples with recurrent pregnancy loss [128] . Evidence-based guidelines should provide recommendations on ways to best manage other causes of OS, including lifestyle modifications (improved diet, smoking cessation, exercise, and weight loss), treatment of clinically relevant varicoceles, and treatment of male accessory gland infection (MAGI) as well as other inflammatory pathologies linked with MOSI (Fig. 3) . The treatment of MAGI with antibiotics, and the decrease in the numbers of ROS-producing seminal leukocytes using anti-inflammatories are likely to add benefit in combination with neutralization of ROS by antioxidant therapy [129] [130] [131] [132] . Treatment success and adherence for the above conditions can be monitored by measuring seminal ORP, as well.
The diagnosis and management of idiopathic male infertility is an integral component of comprehensive sexual and reproductive health services. Idiopathic male infertility can be an emotional burden and financial strain for couples. Current treatment protocols for male infertility are not evidence-based and have the potential risk of complications and increased healthcare-related expenditures [20, 84] . MOSI provides clinicians and patients with a diagnostic classification to guide future research and treatment, while simultaneously reducing apprehension and uncertainty for many couples. A recent consensus guideline by the Eu- [133] . MOSI diagnosis combined with ORP monitoring may provide a more targeted, reliable approach for using antioxidant therapy in both research and practice.
Compared with hormonal EMT and ART, antioxidants are relatively safe, inexpensive and widely available, with a growing body of data supporting their effectiveness at improving semen parameters and live birth rates [53] . Further clinical studies are indicated to directly compare live birth rates among men with MOSI assigned to receive antioxidants versus EMT and ART. Treatment guidelines providing individualized antioxidant therapy protocols based on ORP status for men with MOSI could provide a significant advancement in the management of male factor infertility and facilitate future investigations (Fig. 6) [134] . Guidelines are also necessary to avoid possible overuse of antioxidants leading to reductive stress, which can be as detrimental to sperm health as OS [52, [135] [136] [137] and has been associated with defects in embryogenesis [138] . Supra-physiologic levels of antioxidants may also scavenge the ROS necessary to induce sperm capacitation [32, 38] , leading to infertility. Because antioxidants are readily available online or over-the-counter, they may appear to be a benign first-line treatment. Without clear guidelines for appropriate use, however, there is a risk of overuse in men without evidence of MOSI who may then experience delay accessing more effective therapies (e.g., ART or varicocele repair). Therefore, the oxidative status of male infertility patients should be evaluated before antioxidants are recommended and used only in those cases where MOSI is present.
RECOMMENDATIONS AND FUTURE DIRECTIONS
Therefore, the authors recommend that men with idiopathic infertility should be screened for MOSI using an efficient, inexpensive, high sensitivity/specificity test for ORP such as MiOXSYS, which has practical advantages over alternative techniques (Table 1) . Those men screening positive for MOSI should then undergo more extensive examination to identify treatable triggers and be counseled on appropriate steps to mitigate known causes of OS (e.g., smoking, alcohol consumption, lifestyle risk factors, radiation, toxins, etc.) [139, 140] . ORP testing should be repeated no less than 3 months following the appropriate management plan in infertile men with no explanation for MOSI. Ultimately, infertile men with MOSI should be advised to take antioxidants for a minimum of three months after other known causes of OS have been eliminated. Infertile men without MOSI should be advised against antioxidant therapy. Follow-up testing of ORP levels is recommended to confirm compliance and monitor the efficacy of antioxidant supplementation and continued lifestyle changes 6 to 8 weeks post treatment. We recommend that these approaches be tested in double blind randomized controlled trials to establish whether time to pregnancy and live birth rate is improved in couples where the man is undergoing antioxidant treatment.
With the increasing awareness and understanding of MOSI as a distinct male infertility diagnosis, the development of evidence-based guidelines that target the underlying causes, while balancing the risks and benefits of individual therapies, is imperative. The authors feel that measurement of ORP and stratification of male fertility/infertility on the basis of ORP will be an important tool in the management of infertile couples. The exact role will be defined in future trials and could validate a reclassification of male infertility that incorporates MOSI as a diagnostic category. A better understanding of the etiology of this diagnosis will help identify those men likely to benefit from antioxidant therapy while minimizing the harmful effects of antioxidant overdosing.
